Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis
NCT04189419Phase 2Completed
- Sponsor
- SCM Lifescience Co., Ltd.
- Start
- Aug 2019
- Primary completion
- Jan 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SCM-AGH in acute pancreatitis (AP) (3 arms), sponsored by SCM Lifescience Co., Ltd. Primary endpoints: Change from baseline in modified Marshall score at Day 7 and Change from baseline in CTSI Score at Day 28. Started Aug 2019; status: completed.
02
Drugs
SCM-AGH
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT04189419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189419.